CNSP News and Press, CNS Pharmaceuticals Inc. From 04/28/22

CNS Pharmaceuticals (NASDAQ:CNSP) said on Thursday that it received approval from Spanish drugs regulator AEMPS and Spanish ethics committee CElm Provincial de Sevilla to conduct a study of Berubicin to treat recurrent glioblastoma multiforme (GBM), an aggressive type of brain cancer. The Spa...

CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) PR Newswire Continued advancement of global patient enrollment with Switzerland ...

Researchers have highlighted the important role that some plants play in the manufacture of cancer drugs and why these new sources and plant resources need to be maintained in an effort to avoid overexploitation. For instance, Kew Gardens researcher Melanie-Jayne Howes stated that a chem...

CNS Pharmaceuticals (NASDAQ: CNSP) is leading the charge toward advancing research on the treatment for glioblastoma multiforme (“GBM”) as well as other primary and metastatic brain and CNS cancers. Last year, the company commenced a potentially pivotal clinical trial of its ...

Cancerous tumors are one of the leading causes of death on the planet. Nearly one in six deaths are caused by cancer, and in 2020, there were nearly 10 million cancer-related deaths across the globe. Cancer-related deaths and the number of new cancer cases are... Read more » ...

- Live video webcast events on Thursday, April 14 at 10 AM ET, 11:30 AM ET and 1 PM ET - FRENCHTOWN, NJ / ACCESSWIRE / April 13, 2022 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the continuation of its Virtual Investor S...

Around 700,000 Americans are estimated to live with brain cancer, and by the end of 2022, nearly 90,000 more will have been diagnosed with the deadly disease. In 2020, brain and Central Nervous System (CNS) tumors took more than 200,000 lives worldwide. It is a debilitating condition that ...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be part of a moderated fireside chat during the Virtual Investor Glioblastoma Multiforme (&#x...

CNS Pharmaceuticals to Participate in the Virtual Investor Glioblastoma Multiforme (GBM) Spotlight Event PR Newswire Live video webcast with moderated fireside chat with members from the CNS Pharmaceuticals management team and featuring Key Opinion Leader, Samuel A. ...

CNS Pharmaceuticals is a clinical stage biotechnology company focused on the development of novel treatments for brain tumors The company’s lead product candidate, Berubicin, is a novel anthracycline that is designed to cross the blood-brain barrier The blood-brain barrier ordi...